4-Methylaminorex
| Clinical data | |
|---|---|
| Other names | 4-MAR; 4-MAX; McN-822; McN822 |
| Routes of administration | Oral, Vaporized, Insufflated, Injected |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 62% oral; 79% nasal; 91 - 93.5% smoked; 100% IV |
| Metabolism | Hepatic |
| Elimination half-life | 10-19 hours |
| Excretion | Renal |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C10H12N2O |
| Molar mass | 176.219 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (what is this?) (verify) | |
4-Methylaminorex (4-MAR, 4-MAX) is a stimulant drug of the 2-amino-5-aryloxazoline group that was first synthesized in 1960 by McNeil Laboratories. It is also known by its street name "U4Euh" ("Euphoria"). It is banned in many countries as a stimulant. 4-Methylaminorex has effects comparable to methamphetamine but with a longer duration.